AA
DAWN

ALPS Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History

ALPS Advisors’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.8M Sell
84,092
-212
-0.3% -$2.99K 0.01% 429
2025
Q4 		$786K Buy
84,304
+35,269
+72% +$295K ﹤0.01% 627
2025
Q3 		$346K Sell
49,035
-5,673
-10% -$39K ﹤0.01% 936
2025
Q2 		$356K Sell
54,708
-18,635
-25% -$128K ﹤0.01% 857
2025
Q1 		$582K Sell
73,343
-8,206
-10% -$88.4K ﹤0.01% 572
2024
Q4 		$1.03M Buy
81,549
+12,240
+18% +$170K 0.01% 473
2024
Q3 		$965K Buy
69,309
+1,139
+2% +$16.3K 0.01% 496
2024
Q2 		$939K Buy
68,170
+6,539
+11% +$95.7K 0.01% 479
2024
Q1 		$1.02M Buy
61,631
+1,936
+3% +$29K 0.01% 482
2023
Q4 		$872K Sell
59,695
-4,458
-7% -$54K 0.01% 513
2023
Q3 		$787K Buy
64,153
+1,592
+3% +$20.8K 0.01% 523
2023
Q2 		$747K Buy
62,561
+14,078
+29% +$184K 0.01% 545
2023
Q1 		$648K Sell
48,483
-1,373
-3% -$26.8K 0.01% 543
2022
Q4 		$1.07M Buy
49,856
+9,712
+24% +$199K 0.01% 461
2022
Q3 		$804K Buy
40,144
+3,414
+9% +$72.6K 0.01% 509
2022
Q2 		$657K Sell
36,730
-26,941
-42% -$278K 0.01% 536
2022
Q1 		$632K Sell
63,671
-7,997
-11% -$106K 0.01% 398
2021
Q4 		$1.21M Buy
+71,668
New +$1.47M 0.01% 336

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

ALPS Advisors's DAWN Position: Q1 2026 in Review

ALPS Advisors reduced its Day One Biopharmaceuticals (DAWN) stake by 0.25% in Q1 2026, selling an estimated $2.99K and leaving 84,092 shares worth $1.8M. The position accounts for 0.01% of the portfolio, ranked #429.

ALPS Advisors first reported a position in DAWN in Q4 2021 and has held it in 18 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • ALPS Advisors held 84,092 shares of Day One Biopharmaceuticals worth $1.8M as of Q1 2026.
  • ALPS Advisors sold 212 Day One Biopharmaceuticals shares in Q1 2026, an estimated $2.99K.
  • Day One Biopharmaceuticals made up 0.01% of ALPS Advisors's portfolio in Q1 2026, its #429 holding.
  • ALPS Advisors first reported a position in Day One Biopharmaceuticals in Q4 2021 and has held it in 18 quarters since.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.